Drug Trial Radar · NCT02063360
DDI Study of BMS-663068 With Etravirine (ETR) and/or Darunavir (DVR) + Ritonavir (RTV)
Last checked: Nov 19, 2026Latest source record: Aug 8, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
42
Actual
Start
Feb 1, 2014
Primary completion
May 1, 2014
Study completion May 13, 2014
Sponsor
- Lead sponsor
- ViiV HealthcareGSK (GSK)
- Sponsor type
- Industry
- Collaborators
- GlaxoSmithKline
- First posted
- Feb 14, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Other
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine if there is an interaction in healthy subjects taking BMS-663068 with Darunavir/Ritonavir and/or Etravirine.
Conditions
- Infection, Human Immunodeficiency Virus
Interventions
BMS-663068Drug
BMS-663068
Darunavir (DRV)Drug
Darunavir (DRV)
Ritonavir (RTV)Drug
Ritonavir (RTV)
Etravirine (ETR)Drug
Etravirine (ETR)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum observed plasma concentration (Cmax) of BMS-626529Time frame: 20 timepoints up to day 26
- Area under the concentration-time curve in 1 dosing interval (AUC(TAU)) of BMS-626529Time frame: 20 timepoints up to day 26
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.